• Publications
  • Influence
Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs
Recent research indicates that subjective well-being is a major determinant of medication compliance in schizophrenia. However, it is yet unresolved whether atypical neuroleptics differ regardingExpand
  • 304
  • 32
A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables
  • D. Naber
  • Psychology, Medicine
  • International clinical psychopharmacology
  • 1 September 1995
The benefit of neuroleptic drugs in the treatment of schizophrenic patients is objectively beyond any doubt. However, most patients discontinue their neuroleptic drugs within some months. This lowExpand
  • 323
  • 31
WHO Neuropsychiatric AIDS study, cross-sectional phase II. Neuropsychological and neurological findings.
BACKGROUND The neuropsychological and neurological complications of HIV-1 infection and AIDS were explored within the cross-sectional phase of the WHO Neuropsychiatric AIDS Study. Special attentionExpand
  • 245
  • 19
Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence.
Abstract Objective. – (1) determine which antipsychotic side effects (SE) schizophrenic patients consider the most distressing during treatment with typical antipsychotics, (2) measure the impact ofExpand
  • 222
  • 16
The impact of substance use disorders on clinical outcome in 643 patients with first‐episode psychosis
Objective:  Studies investigating the impact of comorbid substance use disorders (SUD) in psychosis have tended to focus on cross‐sectional data, with few studies examining the effects of substanceExpand
  • 289
  • 15
Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study.
BACKGROUND Naltrexone and acamprosate have been shown to be effective in relapse prevention of alcoholism via different pharmacologic mechanisms. Since it remains uncertain whether both substancesExpand
  • 345
  • 14
  • PDF
Rates and predictors of remission and recovery during 3 years in 392 never‐treated patients with schizophrenia
Objective:  Few studies have prospectively examined remission and recovery as well as their predictors in schizophrenia simultaneously. Aims of the study were to identify remission and recovery ratesExpand
  • 140
  • 14
Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.
OBJECTIVE The purpose of the present study was to evaluate the efficacy and tolerability of olanzapine long-acting injection for maintenance treatment of schizophrenia. METHOD Outpatients withExpand
  • 174
  • 13
Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia
OBJECTIVE To directly compare aripiprazole once-monthly 400mg (AOM 400) and paliperidone palmitate once-monthly (PP) on the Heinrichs-Carpenter Quality-of-Life Scale (QLS), a validated health-relatedExpand
  • 93
  • 13
  • PDF
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
OBJECTIVE The efficacy and safety of olanzapine were compared with those of ziprasidone. METHOD This was a multicenter randomized, double-blind, parallel-group, 28-week study of patients withExpand
  • 133
  • 10